RIBOMIC Inc. announced the publication of the preclinical data of its anti-TGF-1 aptamer demonstrating the enhancement of efficacy of anti-cancer drug, gefitinib, in non-small cell lung cancer xenograft model. The aptamer is being developed in collaboration with Project Associate Professor Masaki Takahashi at Project Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
90 JPY | +1.12% | +4.65% | -16.67% |
1st Jan change | Capi. | |
---|---|---|
-16.67% | 20.97M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.10% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- 4591 Stock
- News Ribomic Inc.
- RIBOMIC Announces Publication of anti-TGF-ß1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug Efficacy